

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AMNEAL PHARMACEUTICALS LLC,
Petitioner
v.

YEDA RESEARCH AND DEVELOPMENT CO., LTD.,
Patent Owner

Case IPR2015-01980
U.S. PATENT NO. 8,399,413 B2
Issue Date: March 19, 2013
Title: LOW FREQUENCY GLATIRAMER ACETATE THERAPY

PETITIONER'S MOTION FOR JOINDER UNDER 35 U.S.C. § 315(c)
AND 37 C.F.R. § 42.22 AND § 42.122(b)

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

TABLE OF CONTENTS

I.	STATEMENT OF PRECISE RELIEF REQUESTED	1
II.	STATEMENT OF MATERIAL FACTS	2
III.	STATEMENT OF REASONS FOR RELIEF REQUESTED	3
A.	Reasons Why Joinder is Appropriate	5
1.	Substantively Identical Petitions.....	5
2.	Consolidated Filings and Discovery	6
B.	No New Grounds of Unpatentability	7
C.	No Impact on IPR Trial Schedule	7
D.	Briefing and Discovery Will Be Simplified.....	7
E.	No Prejudice to Yeda if Proceedings are Joined.....	7
IV.	PROPOSED ORDER	8
V.	CONCLUSION.....	9

TABLE OF AUTHORITIES

Cases

<i>Dell, Inc. v. Network-1 Security Solutions, Inc.</i> , Case IPR2013-00385	4
<i>In re Copaxone 40 mg Consolidated Cases</i> , C.A. No. 14-1171-GMS	2
<i>Motorola Mobility LLC v. Softview LLC</i> , IPR2013-00256 (PTAB June 20, 2013)	7
<i>Mylan Pharmaceuticals Inc. v. Yeda Research & Development Co. Ltd.</i> , Case No. IPR2015-00644	1

Statutes

35 U.S.C. § 315(b)	2
35 U.S.C. § 315(c)	1, 3
35 U.S.C. § 316(b)	5

Other Authorities

37 C.F.R. § 42.1(b)	5
37 C.F.R. § 42.22	3
37 C.F.R. § 42.22	1
37 C.F.R. § 42.122(a)	3
37 C.F.R. § 42.122(b)	1, 3
157 CONG. REC. S1376 (daily ed. Mar. 8, 2011)	5
U.S. Patent No. 8,232,250	2
U.S. Patent No. 8,399,413	1-2
U.S. Patent No. 8,969,302	2

I. STATEMENT OF PRECISE RELIEF REQUESTED

Amneal Pharmaceuticals LLC (“Amneal”) filed the present petition for *inter partes* review IPR2015-01980 (the “Amneal IPR”) and respectfully submits this Motion for Joinder. Pursuant to 35 U.S.C. § 315(c), 37 C.F.R. §§ 42.22 and 42.122(b), Amneal requests institution of an *inter partes* review and joinder with the *inter partes* review concerning the same patent in *Mylan Pharmaceuticals Inc. v. Yeda Research & Development Co. Ltd.*, which is assigned Case No. IPR2015-00644, (the “Mylan IPR”), which was instituted on August 25, 2015.

In accordance with the Board’s Representative Order identifying matters to be addressed in a motion for joinder (Paper No. 15, IPR2013-00004, April 24, 2013), Amneal submits that: (1) joinder is appropriate because it will promote efficient determination of the validity of the ’413 Patent without prejudice to Mylan Pharmaceuticals Inc. (“Mylan”) or Yeda Research & Development Co. Ltd (“Yeda”) (See, e.g., Paper No. 10, IPR2013-00256, June 20, 2013 (granting motion for joinder under similar circumstances)); (2) Amneal’s Petition raises the same grounds of unpatentability as Mylan’s IPR; (3) joinder would not affect the pending schedule in the Mylan IPR nor increase the complexity of that proceeding, minimizing costs; and (4) Amneal is willing to agree to consolidated filings with Mylan to minimize burden and schedule impact.

This Motion for Joinder is timely under 37 C.F.R. §§ 42.22 and 42.122(b), as it is submitted within one month of August 25, 2015, the date on which the Mylan IPR was instituted.

II. STATEMENT OF MATERIAL FACTS

The Amneal IPR and Mylan IPR are among a family of *inter partes* review (“IPR”) proceedings relating to three patents that are being asserted by Yeda Research and Development Co., Ltd. (“Yeda”), along with Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals Industries Ltd., and Teva Neuroscience, Inc., against numerous defendants in the following litigation: *In re Copaxone 40 mg Consolidated Cases*, C.A. No. 14-1171-GMS (consolidated). Accordingly, all petitions for *inter partes* review that have been filed by defendant Mylan and Amneal are timely as prescribed by 35 U.S.C. § 315(b).

Currently, the family of Mylan IPR proceedings relating to the three Yeda patents consists of the following proceedings: IPR2015-00643 (relating to claims 1–20 of U.S. Patent No. 8,232,250); IPR2015-00644 (relating to claims 1–20 of U.S. Patent No. 8,399,413); and IPR2015-00830 (relating to claims 1–12 of U.S. Patent No. 8,969,302).

The petitions for IPR filed by Amneal correspond exactly to the petitions first filed by Mylan against the same patent claims, and are identical to the Mylan

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.